Vimarsana
Biggest News Aggregation in the World

Page 4 - Simcere Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Simcere Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Simcere Pharmaceutical Today - Breaking & Trending Today

Kazia Therapeutics Ltd lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business" - Vimarsana News

Kazia Therapeutics Ltd lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business"

Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business" During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.  These transactions leave Kazia a vastly stronger and more substantial business, with a diversified pipeline of world-class oncology assets. Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it  "a vastly...

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 - Vimarsana News

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 DGAP-News: Evotec SE / Key word(s): Miscellaneous 19.04.2021 / 08:31 The issuer is solely responsible for the content of this announcement. EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ("CMC") EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVEL...

Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 - Vimarsana News

Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ("CMC") EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES HAMBURG, GERMANY / ACCESSWIRE / April 19, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company ha...

PRESS RELEASE: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 - Vimarsana News

PRESS RELEASE: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Message : Required fields DGAP-News: Evotec SE / Key word(s): Miscellaneous Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 2021-04-19 / 08:31 The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- . EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 . KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC ...

Kazia Therapeutics presents PK data for paxalisib at AACR meeting - Vimarsana News

Kazia Therapeutics presents PK data for paxalisib at AACR meeting

Kazia Therapeutics Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian  oncology-focused drug development company, is pleased to share new data from its  ongoing phase II study of paxalisib in glioblastoma, the most common and most aggressive form of primary brain cancer. The data is the subject of a poster presentation at the American Association of Cancer  Research (AACR) Annual Meeting, which is being held virtually from 10-15 April 2021, and  from 17-21 May 2021. Key Points Pharmacokinetic (PK) data, which shows how long paxalisib remains in the human  body, stro...